miRNA analysis in pancreatic cancer: the Dartmouth experience
Tóm tắt
Pancreatic cancer is considered one of the most lethal cancers being the fourth leading cause of cancer deaths in adults in the United States because of the lack of early signs and symptoms and the lack of early detection. Pancreatic ductal adenocarcinoma (PDAC) is the most common histological type among pancreatic cancers, representing 80%–90% of all solid tumors of the pancreas. The majority of PDAC develops from three precursor lesions: pancreatic intraepithelial neoplasia, intraductual papillary mucinous neoplasm and mucinous cystic neoplasm. Although histologic tissue evaluation remains the gold standard for diagnosis, endoscopic ultrasound-guided fine needle aspiration has become the preferred modality for obtaining pathologic confirmation. At Dartmouth-Hitchcock Medical Center (DHMC),we have developed and validated a microRNA (miRNA) panel for patients with pancreatic diseases that can be used in association with the gold standard method for diagnosis. miRNAs have an important role in biological processes, such as apoptosis, metabolism, cell growth and differentiation. In cancer, miRNAs can be classified as either oncogenic or tumor suppressor according to their function in the carcinogenic process. In this study, we describe the expression of many miRNA in benign and malignant pancreatic tissues as well as their clinical significance. For this reason, miRNAs have been considered potential biomarkers of pancreatic diseases that could potentially contribute to an early diagnosis, predict disease progression, accurately monitor disease, contribute to better treatment strategies and reduce mortality by improving disease management.
Từ khóa
Tài liệu tham khảo
1998, Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas, Am J Surg Pathol, 22, 163, 10.1097/00000478-199802000-00003
2015, MicroRNA signaling pathway network in pancreatic ductal adenocarcinoma, Sun J Genet Genomics, 42, 563, 10.1016/j.jgg.2015.07.003
2010, Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras, Int J Radiat Oncol Biol Phys, 76, 5, 10.1016/j.ijrobp.2009.08.028
2000, Progression model for pancreatic cancer, Clin Cancer Res, 6, 2969
2016, MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions, World J Gastrointest Oncol, 8, 18, 10.4251/wjgo.v8.i1.18
2012, Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer, Clin Chem, 58, 610, 10.1373/clinchem.2011.172767
2011, Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer, Pancreatology, 11, 40, 10.1159/000323502
2011, Pancreatic cancer: understanding and overcoming chemoresistance, Nat Rev Gastroenterol Hepatol, 8, 27, 10.1038/nrgastro.2010.188
2011, Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer, Pancreatology, 11, 40, 10.1159/000323502
2007, Detecting early pancreatic cancer: problems and prospects, Semin Oncol, 34, 284, 10.1053/j.seminoncol.2007.05.005
2008, Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues, Clin Chem, 54, 1716, 10.1373/clinchem.2008.109603
2016, MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions, World J Gastrointest Oncol, 8, 18, 10.4251/wjgo.v8.i1.18
2013, Targeting microRNAs in pancreatic cancer: microplayers in the big game, Cancer Res, 73, 6541, 10.1158/0008-5472.CAN-13-1288
2016, MicroRNAs: a puzzling tool in cancer diagnostics and therapy, Anticancer Res, 36, 5571, 10.21873/anticanres.11142
2008, Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues, Clin Chem, 54, 1716, 10.1373/clinchem.2008.109603
2010, Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras, Int J Radiat Oncol Biol Phys, 76, 5, 10.1016/j.ijrobp.2009.08.028
2014, A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile, Am J Gastroenterol, 109, 1942, 10.1038/ajg.2014.331
2007, Detecting early pancreatic cancer: problems and prospects, Semin Oncol, 34, 284, 10.1053/j.seminoncol.2007.05.005
2000, Progression model for pancreatic cancer, Clin Cancer Res, 6, 2969
2015, Autoimmune pancreatitis: a succinct overview, J Pancreas, 16, 239
2016, Advance in microRNA as a potential biomarker for early detection of pancreatic cancer, Biomark Res, 4, 20, 10.1186/s40364-016-0074-3
2016, MicroRNA therapeutics: discovering novel targets and developing specific therapy, Perspect Clin Res, 7, 68, 10.4103/2229-3485.179431
2009, Surgical pathology of the GI tract, liver, biliary tract and pancreas, 1086
2015, Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer, Target Oncol, 10, 535, 10.1007/s11523-015-0360-2
2016, MicroRNA therapeutics: discovering novel targets and developing specific therapy, Perspect Clin Res, 7, 68, 10.4103/2229-3485.179431
2014, A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer, Clin Gastroenterol Hepatol, 12, 1717, 10.1016/j.cgh.2014.02.038
1998, Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma, Ann Diagn Pathol, 2, 286, 10.1016/S1092-9134(98)80020-8
2012, Differential signature of fecal microRNAs in patients with pancreatic cancer, Mol Med Rep, 6, 201
2001, Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions, Am J Surg Pathol, 25, 579, 10.1097/00000478-200105000-00003
2014, A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer, Clin Gastroenterol Hepatol, 12, 1717, 10.1016/j.cgh.2014.02.038
2013, Targeting microRNAs in pancreatic cancer: microplayers in the big game, Cancer Res, 73, 6541, 10.1158/0008-5472.CAN-13-1288
2012, Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer, Clin Chem, 58, 610, 10.1373/clinchem.2011.172767
2009, Misdiagnosis of autoimmune pancreatitis: a caution to clinicians, Am J Gastroenterol, 104, 1620, 10.1038/ajg.2008.89
2013, MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm, Cancer Genet, 206, 217, 10.1016/j.cancergen.2013.05.020
2011, Pancreatic cancer: understanding and overcoming chemoresistance, Nat Rev Gastroenterol Hepatol, 8, 27, 10.1038/nrgastro.2010.188
2009, Surgical pathology of the GI tract, liver, biliary tract and pancreas, 1086
2009, Misdiagnosis of autoimmune pancreatitis: a caution to clinicians, Am J Gastroenterol, 104, 1620, 10.1038/ajg.2008.89
2016, MicroRNAs: a puzzling tool in cancer diagnostics and therapy, Anticancer Res, 36, 5571, 10.21873/anticanres.11142
2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 368, 1685, 10.1056/NEJMoa1209026
2016, Advance in microRNA as a potential biomarker for early detection of pancreatic cancer, Biomark Res, 4, 20, 10.1186/s40364-016-0074-3
2016, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application, Cell Oncol, 39, 295, 10.1007/s13402-016-0275-7
2009, MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease, Cancer Prev Res, 2, 807, 10.1158/1940-6207.CAPR-09-0094
1998, Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma, Ann Diagn Pathol, 2, 286, 10.1016/S1092-9134(98)80020-8
2015, Circulating RNAs as new biomarkers for detecting pancreatic cancer, World J Gastroenterol, 21, 8527, 10.3748/wjg.v21.i28.8527
2014, MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer, Am J Cancer Res, 4, 663
2007, In: Atlas of Tumor Pathology
2013, Targeting microRNAs in pancreatic cancer: microplayers in the big game, Cancer Res, 73, 6541, 10.1158/0008-5472.CAN-13-1288
2015, Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis, Int J Oncol, 47, 1203, 10.3892/ijo.2015.3129
2014, MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer, Am J Cancer Res, 4, 663
2015, Autoimmune pancreatitis: a succinct overview, J Pancreas, 16, 239
2015, Circulating RNAs as new biomarkers for detecting pancreatic cancer, World J Gastroenterol, 21, 8527, 10.3748/wjg.v21.i28.8527
2015, Contribution of microRNA analysis to characterisation of pancreatic lesions: a review, J Clin Pathol, 68, 859, 10.1136/jclinpath-2015-203246
2013, Targeting microRNAs in pancreatic cancer: microplayers in the big game, Cancer Res, 73, 6541, 10.1158/0008-5472.CAN-13-1288
2013, Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer, Am J Gastroenterol, 108, 1352, 10.1038/ajg.2013.167
2009, MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease, Cancer Prev Res, 2, 807, 10.1158/1940-6207.CAPR-09-0094
2013, MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm, Cancer Genet, 206, 217, 10.1016/j.cancergen.2013.05.020
2007, In: Atlas of Tumor Pathology
1998, Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas, Am J Surg Pathol, 22, 163, 10.1097/00000478-199802000-00003
2012, Differential signature of fecal microRNAs in patients with pancreatic cancer, Mol Med Rep, 6, 201
2016, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application, Cell Oncol, 39, 295, 10.1007/s13402-016-0275-7
2015, Contribution of microRNA analysis to characterisation of pancreatic lesions: a review, J Clin Pathol, 68, 859, 10.1136/jclinpath-2015-203246
2014, A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile, Am J Gastroenterol, 109, 1942, 10.1038/ajg.2014.331
2001, Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions, Am J Surg Pathol, 25, 579, 10.1097/00000478-200105000-00003
2015, MicroRNA signaling pathway network in pancreatic ductal adenocarcinoma, Sun J Genet Genomics, 42, 563, 10.1016/j.jgg.2015.07.003
2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 368, 1685, 10.1056/NEJMoa1209026
2010, The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis, Clin Chem, 56, 1107, 10.1373/clinchem.2010.144709
2013, Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer, Am J Gastroenterol, 108, 1352, 10.1038/ajg.2013.167
2015, Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis, Int J Oncol, 47, 1203, 10.3892/ijo.2015.3129
2015, Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer, Target Oncol, 10, 535, 10.1007/s11523-015-0360-2
2009, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells, PLoS One, 4, e6816, 10.1371/journal.pone.0006816
2009, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells, PLoS One, 4, e6816, 10.1371/journal.pone.0006816